Lopressor and Dermatitis bullous - a phase IV clinical study of FDA data

Summary:

Dermatitis bullous is reported as a side effect among people who take Lopressor (metoprolol tartrate), especially for people who are male, 60+ old, have been taking the drug for 10+ years also take Lasix, and have Breast cancer.

The phase IV clinical study analyzes which people have Dermatitis bullous when taking Lopressor. It is created by eHealthMe based on reports of 32,072 people who have side effects when taking Lopressor from the FDA, and is updated regularly.

What is Lopressor?

Lopressor has active ingredients of metoprolol tartrate. It is often used in high blood pressure. eHealthMe is studying from 33,152 Lopressor users. Check the latest studies of Lopressor.

What is Dermatitis bullous?

Dermatitis bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid) is found to be associated with 666 drugs and 949 conditions by eHealthMe. Check the latest studies of Dermatitis bullous.

On Jul, 06, 2026

32,072 people reported to have side effects when taking Lopressor.
Among them, 16 people (0.05%) have Dermatitis bullous.

Could Lopressor cause Dermatitis bullous?

Among these 16 people:

How long have people been on Lopressor when they have Dermatitis bullous? *

What is the gender of people who have Dermatitis bullous when taking Lopressor? *

female: 37.5 %
male: 62.5 %

What is the age of people who have Dermatitis bullous when taking Lopressor? *

What are other drugs people take besides Lopressor? *

What are other side effects people have besides Dermatitis bullous? *

Urticaria (rash of round, red welts on the skin that itch intensely): 2 people, 12.50%
Oedema Peripheral (superficial swelling): 2 people, 12.50%
Thrombocytopenia (decrease of platelets in blood): 2 people, 12.50%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 2 people, 12.50%
Rashes (redness): 2 people, 12.50%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 6.25%
Feeling Hot: 1 person, 6.25%
Erythema Multiforme (a type of hypersensitivity reaction): 1 person, 6.25%
Ecchymosis (a discoloration of the skin resulting from bleeding underneath): 1 person, 6.25%
Dyspnea (difficult or laboured breathing): 1 person, 6.25%

What are the existing conditions these people have? *

Breast Cancer: 2 people, 12.50%
Type 2 Diabetes: 1 person, 6.25%
Respiratory Tract Infection: 1 person, 6.25%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 1 person, 6.25%
High Blood Cholesterol: 1 person, 6.25%
Diabetes: 1 person, 6.25%
Chronic Leukaemia (long lasting blood cell cancer): 1 person, 6.25%
Cardiac Failure: 1 person, 6.25%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 6.25%
Breast Cancer Metastatic: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Lopressor and have Dermatitis bullous?

- Check whether Dermatitis bullous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lopressor:

Lopressor (33,152 reports)

Browse all side effects of Lopressor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis bullous:

Dermatitis bullous (666 drugs)

Browse all the conditions that are associated with Dermatitis bullous:

Dermatitis bullous (949 conditions)

Related publications that referenced our studies

Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on metoprolol tartrate (the active ingredients of Lopressor) and Lopressor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.